RESUMEN
BACKGROUND: In sub-Saharan Africa, the efficacy of intermittent preventive therapy in pregnancy with sulphadoxine-pyrimethamine (IPTp-SP) for malaria in pregnancy is threatened by parasite resistance. We conducted an individual-participant data (IPD) meta-analysis to assess the efficacy of intermittent screening with malaria rapid diagnostic tests (RDTs) and treatment of RDT-positive women with artemisinin-based combination therapy (ISTp-ACT) compared to IPTp-SP, and understand the importance of subpatent infections. METHODS: We searched MEDLINE and the Malaria-in-Pregnancy Library on May 6, 2021 for trials comparing ISTp-ACT and IPTp-SP. Generalised linear regression was used to compare adverse pregnancy outcomes (composite of small-for-gestational-age, low birthweight (LBW), or preterm delivery) and peripheral or placental Plasmodium falciparum at delivery. The effects of subpatent (PCR-positive, RDT/microscopy-negative) infections were assessed in both arms pooled using multi-variable fixed-effect models adjusting for the number of patent infections. PROSPERO registration: CRD42016043789. FINDINGS: Five trials conducted between 2007 and 2014 contributed (10,821 pregnancies), two from high SP-resistance areas where dhfr/dhps quintuple mutant parasites are saturated, but sextuple mutants are still rare (Kenya and Malawi), and three from low-resistance areas (West-Africa). Four trials contributed IPD data (N=10,362). At delivery, the prevalence of any malaria infection (relative risk [RR]=1.08, 95% CI 1.00-1.16, I2=67.0 %) and patent infection (RR=1.02, 0.61-1.16, I2=0.0%) were similar. Subpatent infections were more common in ISTp recipients (RR=1.31, 1.05-1.62, I2=0.0%). There was no difference in adverse pregnancy outcome (RR=1.00, 0.96-1.05; studies=4, N=9,191, I2=54.5%). Subpatent infections were associated with LBW (adjusted RR=1.13, 1.07-1.19), lower mean birthweight (adjusted mean difference=32g, 15-49), and preterm delivery (aRR=1.35, 1.15-1.57). INTERPRETATION: ISTp-ACT was not superior to IPTp-SP and may result in more subpatent infections than the existing IPTp-SP policy. Subpatent infections were associated with increased LBW and preterm delivery. More sensitive diagnostic tests are needed to detect and treat low-grade infections. FUNDING: Centers for Disease Control and Prevention and Worldwide Antimalarial Resistance Network.
RESUMEN
One hundred twenty-five million pregnant women are at risk for contracting malaria, a preventable cause of maternal and infant morbidity and death. Malaria parasites contribute to adverse pregnancy and birth outcomes due to their preferential accumulation in placental intervillous spaces. Pregnant women are particularly vulnerable to malaria infections, and malaria infections during pregnancy put their fetuses at risk. Malaria in pregnancy is associated with anemia, stillbirth, low birth weight and maternal and fetal death. We review the challenges to diagnosing malaria in pregnancy, as well as strategies to prevent and treat malaria in pregnancy. Finally, we discuss the current gaps in knowledge and potential areas for continued research.
Asunto(s)
Antimaláricos/uso terapéutico , Infecciones por VIH/transmisión , Malaria/transmisión , Complicaciones Infecciosas del Embarazo/parasitología , Complicaciones Parasitarias del Embarazo/epidemiología , Coinfección , Femenino , Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/epidemiología , Investigación sobre Servicios de Salud , Humanos , Recién Nacido , Transmisión Vertical de Enfermedad Infecciosa/prevención & control , Malaria/tratamiento farmacológico , Malaria/epidemiología , Vacunas contra la Malaria , Embarazo , Complicaciones Infecciosas del Embarazo/epidemiología , Complicaciones Infecciosas del Embarazo/prevención & control , Complicaciones Parasitarias del Embarazo/tratamiento farmacológico , Resultado del Embarazo , Mujeres EmbarazadasRESUMEN
Nearly two thirds of persons suspected of having tickborne illness in central North Carolina, USA, were not tested for Ehrlichia. Failure to test may have resulted in a missed diagnosis for ≈13% of these persons, who were therefore substantially less likely to receive antimicrobial treatment and to have follow-up testing performed.
Asunto(s)
Vectores Arácnidos/microbiología , Ehrlichia/inmunología , Ehrlichiosis/diagnóstico , Ixodidae/microbiología , Enfermedades por Picaduras de Garrapatas/diagnóstico , Adulto , Anciano , Animales , Antibacterianos/uso terapéutico , Estudios de Cohortes , Demografía , Doxiciclina/uso terapéutico , Ehrlichia/aislamiento & purificación , Ehrlichiosis/tratamiento farmacológico , Ehrlichiosis/epidemiología , Ehrlichiosis/microbiología , Femenino , Humanos , Masculino , Persona de Mediana Edad , North Carolina/epidemiología , Estudios Retrospectivos , Estudios Seroepidemiológicos , Enfermedades por Picaduras de Garrapatas/tratamiento farmacológico , Enfermedades por Picaduras de Garrapatas/epidemiología , Enfermedades por Picaduras de Garrapatas/microbiologíaRESUMEN
Hepatitis B virus (HBV) is a significant public health issue that has not been adequately addressed, especially in the high-prevalence region of Africa. Despite the incorporation of HBV vaccines into the Expanded Program on Immunization, children continue to be infected with HBV through maternal-to-child transmission (MTCT). The addition of a birth dose of HBV vaccine would be a cost-effective method to reduce MTCT. Birth-dose HBV vaccine policies have been adopted in the Western Pacific region but not yet in Africa. Even better protection against HBV MTCT can be achieved by treatment of pregnant women with high HBV viral loads with tenofovir. Tenofovir is already widely used in prevention of HIV MTCT (PMTCT) programs. We suggest that existing HIV PMTCT programs could be expanded to deliver care for HBV-infected pregnant women. With appropriate adoption of birth-dose vaccination policies and expansion of PMTCT programs, elimination of HBV MTCT in Africa is achievable.
Asunto(s)
Vacunas contra Hepatitis B/administración & dosificación , Vacunas contra Hepatitis B/inmunología , Hepatitis B/prevención & control , Hepatitis B/transmisión , Transmisión Vertical de Enfermedad Infecciosa/prevención & control , Complicaciones Infecciosas del Embarazo/virología , África del Sur del Sahara/epidemiología , Antivirales/administración & dosificación , Antivirales/farmacología , Niño , Femenino , Infecciones por VIH/prevención & control , Hepatitis B/virología , Virus de la Hepatitis B/inmunología , Humanos , Programas de Inmunización , Embarazo , Complicaciones Infecciosas del Embarazo/prevención & control , Tenofovir/administración & dosificación , Tenofovir/farmacología , Carga ViralRESUMEN
BACKGROUND: In Africa, most plasmodium infections during pregnancy remain asymptomatic, yet are associated with maternal anemia and low birthweight. WHO recommends intermittent preventive therapy in pregnancy with sulfadoxine-pyrimethamine (IPTp-SP). However, sulfadoxine-pyrimethamine (SP) efficacy is threatened by high-level parasite resistance. We conducted a trial to evaluate the efficacy and safety of scheduled intermittent screening with malaria rapid diagnostic tests (RDTs) and treatment of RDT-positive women with dihydroartemisinin-piperaquine (DP) as an alternative strategy to IPTp-SP. METHODS AND FINDINGS: This was an open-label, two-arm individually randomized superiority trial among HIV-seronegative women at three sites in Malawi with high SP resistance. The intervention consisted of three or four scheduled visits in the second and third trimester, 4 to 6 wk apart. Women in the IPTp-SP arm received SP at each visit. Women in the intermittent screening and treatment in pregnancy with DP (ISTp-DP) arm were screened for malaria at every visit and treated with DP if RDT-positive. The primary outcomes were adverse live birth outcome (composite of small for gestational age, low birthweight [<2,500 g], or preterm birth [<37 wk]) in paucigravidae (first or second pregnancy) and maternal or placental plasmodium infection at delivery in multigravidae (third pregnancy or higher). Analysis was by intention to treat. Between 21 July 2011 and 18 March 2013, 1,873 women were recruited (1,155 paucigravidae and 718 multigravidae). The prevalence of adverse live birth outcome was similar in the ISTp-DP (29.9%) and IPTp-SP (28.8%) arms (risk difference = 1.08% [95% CI -3.25% to 5.41%]; all women: relative risk [RR] = 1.04 [95% CI 0.90-1.20], p = 0.625; paucigravidae: RR = 1.10 [95% CI 0.92-1.31], p = 0.282; multigravidae: RR = 0.92 [95% CI 0.71-1.20], p = 0.543). The prevalence of malaria at delivery was higher in the ISTp-DP arm (48.7% versus 40.8%; risk difference = 7.85%, [95% CI 3.07%-12.63%]; all women: RR = 1.19 [95% CI 1.07-1.33], p = 0.007; paucigravidae: RR = 1.16 [95% CI 1.04-1.31], p = 0.011; multigravidae: RR = 1.29 [95% CI 1.02-1.63], p = 0.037). Fetal loss was more common with ISTp-DP (2.6% versus 1.3%; RR = 2.06 [95% CI 1.01-4.21], p = 0.046) and highest among non-DP-recipients (3.1%) in the ISTp-DP arm. Limitations included the open-label design. CONCLUSIONS: Scheduled screening for malaria parasites with the current generation of RDTs three to four times during pregnancy as part of focused antenatal care was not superior to IPTp-SP in this area with high malaria transmission and high SP resistance and was associated with higher fetal loss and more malaria at delivery. TRIAL REGISTRATION: Pan African Clinical Trials Registry PACTR201103000280319; ISRCTN Registry ISRCTN69800930.
Asunto(s)
Antimaláricos/efectos adversos , Artemisininas/efectos adversos , Pruebas Diagnósticas de Rutina , Malaria/prevención & control , Complicaciones Parasitarias del Embarazo/prevención & control , Pirimetamina/efectos adversos , Quinolinas/efectos adversos , Sulfadoxina/efectos adversos , Adolescente , Adulto , Pruebas Diagnósticas de Rutina/estadística & datos numéricos , Combinación de Medicamentos , Femenino , Humanos , Malaui , Embarazo , Adulto JovenRESUMEN
BACKGROUND: Owing to increasing sulfadoxine-pyrimethamine (SP) resistance in sub-Saharan Africa, monitoring the effectiveness of intermittent preventive therapy in pregnancy (IPTp) with SP is crucial. METHODS: Between 2009 and 2013, both the efficacy of IPTp-SP at clearing existing peripheral malaria infections and the effectiveness of IPTp-SP at reducing low birth weight (LBW) were assessed among human immunodeficiency virus-uninfected participants in 8 sites in 6 countries. Sites were classified as high, medium, or low resistance after measuring parasite mutations conferring SP resistance. An individual-level prospective pooled analysis was conducted. RESULTS: Among 1222 parasitemic pregnant women, overall polymerase chain reaction-uncorrected and -corrected failure rates by day 42 were 21.3% and 10.0%, respectively (39.7% and 21.1% in high-resistance areas; 4.9% and 1.1% in low-resistance areas). Median time to recurrence decreased with increasing prevalence of Pfdhps-K540E. Among 6099 women at delivery, IPTp-SP was associated with a 22% reduction in the risk of LBW (prevalence ratio [PR], 0.78; 95% confidence interval [CI], .69-.88; P < .001). This association was not modified by insecticide-treated net use or gravidity, and remained significant in areas with high SP resistance (PR, 0.81; 95% CI, .67-.97; P = .02). CONCLUSIONS: The efficacy of SP to clear peripheral parasites and prevent new infections during pregnancy is compromised in areas with >90% prevalence of Pfdhps-K540E. Nevertheless, in these high-resistance areas, IPTp-SP use remains associated with increases in birth weight and maternal hemoglobin. The effectiveness of IPTp in eastern and southern Africa is threatened by further increases in SP resistance and reinforces the need to evaluate alternative drugs and strategies for the control of malaria in pregnancy.
Asunto(s)
Antimaláricos/farmacología , Resistencia a Medicamentos , Recién Nacido de Bajo Peso , Malaria/prevención & control , Complicaciones Infecciosas del Embarazo/prevención & control , Pirimetamina/farmacología , Sulfadoxina/farmacología , Adulto , África del Sur del Sahara/epidemiología , Sustitución de Aminoácidos , Antimaláricos/administración & dosificación , Dihidropteroato Sintasa/genética , Combinación de Medicamentos , Quimioterapia/métodos , Femenino , Humanos , Recién Nacido , Malaria/complicaciones , Proteínas Mutantes/genética , Plasmodium falciparum/enzimología , Embarazo , Estudios Prospectivos , Pirimetamina/administración & dosificación , Sulfadoxina/administración & dosificación , Resultado del Tratamiento , Adulto JovenRESUMEN
BACKGROUND: The A581 G: mutation in the gene encoding Plasmodium falciparum dihydropteroate synthase (dhps), in combination with the quintuple mutant involving mutations in both dhps and the gene encoding dihydrofolate reductase (dhfr), the so-called sextuple mutant, has been associated with increased placental inflammation and decreased infant birth weight among women receiving intermittent preventive treatment with sulfadoxine-pyrimethamine (IPTp-SP) during pregnancy. METHODS: Between 2009 and 2011, delivering women without human immunodeficiency virus infection were enrolled in an observational study of IPTp-SP effectiveness in Malawi. Parasites were detected by polymerase chain reaction (PCR); positive samples were sequenced to genotype the dhfr and dhps loci. The presence of K540 E: in dhps was used as a marker for the quintuple mutant. RESULTS: Samples from 1809 women were analyzed by PCR; 220 (12%) were positive for P. falciparum. A total of 202 specimens were genotyped at codon 581 of dhps; 17 (8.4%) harbored the sextuple mutant. The sextuple mutant was associated with higher risks of patent infection in peripheral blood (adjusted prevalence ratio [aPR], 2.76; 95% confidence interval [CI], 1.82-4.18) and placental blood (aPR 3.28; 95% CI, 1.88-5.78) and higher parasite densities. Recent SP use was not associated with increased parasite densities or placental pathology overall and among women with parasites carrying dhps A581 G: . CONCLUSIONS: IPTp-SP failed to inhibit parasite growth but did not exacerbate pathology among women infected with sextuple-mutant parasites. New interventions to prevent malaria during pregnancy are needed urgently.
Asunto(s)
Dihidropteroato Sintasa/genética , Resistencia a Medicamentos , Malaria Falciparum/prevención & control , Mutación Missense , Plasmodium falciparum/enzimología , Pirimetamina/farmacología , Pirimetamina/uso terapéutico , Sulfadoxina/farmacología , Sulfadoxina/uso terapéutico , ADN Protozoario/química , ADN Protozoario/genética , Combinación de Medicamentos , Femenino , Genotipo , Humanos , Recién Nacido , Malaria Falciparum/parasitología , Malaui , Plasmodium falciparum/genética , Plasmodium falciparum/aislamiento & purificación , Mutación Puntual , Reacción en Cadena de la Polimerasa , Embarazo , Análisis de Secuencia de ADN , Tetrahidrofolato Deshidrogenasa/genética , Resultado del TratamientoRESUMEN
BACKGROUND: Intermittent Preventive Treatment in pregnancy (IPTp) with sulphadoxine-pyrimethamine (SP) is widely used for the control of malaria in pregnancy in Africa. The emergence of resistance to SP is a concern requiring monitoring the effectiveness of SP for IPTp. METHODS: This was an in-vivo efficacy study to determine the parasitological treatment response and the duration of post-treatment prophylaxis among asymptomatic pregnant women receiving SP as part of IPTp in Mali and Burkina-Faso. The primary outcome was the PCR-unadjusted % of patients with parasites recurrence by day 42 defined as a positive diagnostic test by malaria smear at any visit between days 4 and 42. Treatment failure was based on the standard World Health Organization criteria. The therapeutic response was estimated using the Kaplan-Meier curve. RESULTS: A total of 580 women were enrolled in Mali (N=268) and Burkina-Faso (N=312) and followed weekly for 42 days. Among these, 94.3% completed the follow-up. The PCR-unadjusted cumulative risk of recurrence by day 42 was 4.9% overall, and 3.2% and 6.5% in Mali and Burkina Faso respectively (Hazard Ratio [HR] =2.14, 95%, CI [0.93-4.90]; P=0.070), and higher among the primi- and secundigravida (6.4%) than multigravida (2.2%, HR=3.01 [1.04-8.69]; P=0.042). The PCR-adjusted failure risk was 1.1% overall (Mali 0.8%, Burkina-Faso 1.4%). The frequencies (95% CI) of the dhfr double and triple mutant and dhps 437 and 540 alleles mutant genotype at enrolment were 24.2% (23.7-25.0), 4.7% (4.4-5.0), and 21.4% (20.8-22.0) and 0.37% (0.29-0.44) in Mali, and 7.1% (6.5-7.7), 44.9% (43.8-46.0) and 75.3% (74.5-76.2) and 0% in Burkina-Faso, respectively. There were no dhfr 164L or dhps 581G mutations. CONCLUSION: SP remains effective at clearing existing infections when provided as IPTp to asymptomatic pregnant women in Mali and Burkina. Continued monitoring of IPTp-SP effectiveness, including of the impact on birth parameters in this region is essential.
Asunto(s)
Antimaláricos/uso terapéutico , Resistencia a Medicamentos , Malaria/tratamiento farmacológico , Pirimetamina/uso terapéutico , Sulfadoxina/uso terapéutico , Adolescente , Adulto , Infecciones Asintomáticas/epidemiología , Infecciones Asintomáticas/terapia , Biomarcadores/sangre , Burkina Faso/epidemiología , Pruebas con Sangre Seca , Combinación de Medicamentos , Femenino , Estudios de Seguimiento , Humanos , Estimación de Kaplan-Meier , Malaria/epidemiología , Malí/epidemiología , Carga de Parásitos , Reacción en Cadena de la Polimerasa , Embarazo , Adulto JovenRESUMEN
BACKGROUND: Breastfeeding is a leading cause of infant HIV-1 infection in the developing world, yet only a minority of infants exposed to HIV-1 via breastfeeding become infected. As a genetic bottleneck severely restricts the number of postnatally-transmitted variants, genetic or phenotypic properties of the virus Envelope (Env) could be important for the establishment of infant infection. We examined the efficiency of virologic functions required for initiation of infection in the gastrointestinal tract and the neutralization sensitivity of HIV-1 Env variants isolated from milk of three postnatally-transmitting mothers (n = 13 viruses), five clinically-matched nontransmitting mothers (n = 16 viruses), and seven postnatally-infected infants (n = 7 postnatally-transmitted/founder (T/F) viruses). RESULTS: There was no difference in the efficiency of epithelial cell interactions between Env virus variants from the breast milk of transmitting and nontransmitting mothers. Moreover, there was similar efficiency of DC-mediated trans-infection, CCR5-usage, target cell fusion, and infectivity between HIV-1 Env-pseudoviruses from nontransmitting mothers and postnatal T/F viruses. Milk Env-pseudoviruses were generally sensitive to neutralization by autologous maternal plasma and resistant to breast milk neutralization. Infant T/F Env-pseudoviruses were equally sensitive to neutralization by broadly-neutralizing monoclonal and polyclonal antibodies as compared to nontransmitted breast milk Env variants. CONCLUSION: Postnatally-T/F Env variants do not appear to possess a superior ability to interact with and cross a mucosal barrier or an exceptional resistance to neutralization that define their capability to initiate infection across the infant gastrointestinal tract in the setting of preexisting maternal antibodies.
Asunto(s)
Tracto Gastrointestinal/virología , Infecciones por VIH/transmisión , VIH-1/genética , Transmisión Vertical de Enfermedad Infecciosa , Leche Humana/inmunología , Productos del Gen env del Virus de la Inmunodeficiencia Humana/genética , Anticuerpos Neutralizantes/sangre , Anticuerpos Neutralizantes/metabolismo , Lactancia Materna , Estudios de Cohortes , Femenino , Tracto Gastrointestinal/inmunología , Anticuerpos Anti-VIH/sangre , Anticuerpos Anti-VIH/metabolismo , Infecciones por VIH/inmunología , VIH-1/patogenicidad , Humanos , Lactante , Leche Humana/virología , Pruebas de Neutralización , Filogenia , Análisis de Secuencia de ARN , Carga ViralRESUMEN
BACKGROUND: The risk of postnatal HIV transmission is associated with the magnitude of the milk virus load. While HIV-specific cellular immune responses control systemic virus load and are detectable in milk, the contribution of these responses to the control of virus load in milk is unknown. METHODS: We assessed the magnitude of the immunodominant GagRY11 and subdominant EnvKY9-specific CD8+ T lymphocyte response in blood and milk of 10 A*3002+, HIV-infected Malawian women throughout the period of lactation and correlated this response to milk virus RNA load and markers of breast inflammation. RESULTS: The magnitude and kinetics of the HIV-specific CD8+ T lymphocyte responses were discordant in blood and milk of the right and left breast, indicating independent regulation of these responses in each breast. However, there was no correlation between the magnitude of the HIV-specific CD8+ T lymphocyte response and the milk virus RNA load. Further, there was no correlation between the magnitude of this response and markers of breast inflammation. CONCLUSIONS: The magnitude of the HIV-specific CD8+ T lymphocyte response in milk does not appear to be solely determined by the milk virus RNA load and is likely only one of the factors contributing to maintenance of low virus load in milk.
Asunto(s)
Linfocitos T CD8-positivos/virología , VIH/inmunología , Membrana Mucosa/inmunología , ARN Viral/análisis , Carga Viral , Mama/metabolismo , Mama/virología , Linfocitos T CD8-positivos/inmunología , Femenino , Humanos , Cinética , Lactancia , Malaui , Leche Humana/inmunología , Leche Humana/virología , Membrana Mucosa/virología , Especificidad del Receptor de Antígeno de Linfocitos T/inmunologíaRESUMEN
Despite months of mucosal virus exposure, the majority of breastfed infants born to HIV-infected mothers do not become infected, raising the possibility that immune factors in milk inhibit mucosal transmission of HIV. HIV Envelope (Env)-specific antibodies are present in the milk of HIV-infected mothers, but little is known about their virus-specific functions. In this study, HIV Env-specific antibody binding, autologous and heterologous virus neutralization, and antibody-dependent cell cytotoxicity (ADCC) responses were measured in the milk and plasma of 41 HIV-infected lactating women. Although IgA is the predominant antibody isotype in milk, HIV Env-specific IgG responses were higher in magnitude than HIV Env-specific IgA responses in milk. The concentrations of anti-HIV gp120 IgG in milk and plasma were directly correlated (r = 0.75; P < 0.0001), yet the response in milk was 2 logarithm units lower than in plasma. Similarly, heterologous virus neutralization (r = 0.39; P = 0.010) and ADCC activity (r = 0.64; P < 0.0001) in milk were directly correlated with that in the systemic compartment but were 2 log units lower in magnitude. Autologous neutralization was rarely detected in milk. Milk heterologous virus neutralization titers correlated with HIV gp120 Env-binding IgG responses but not with IgA responses (r = 0.71 and P < 0.0001, and r = 0.17 and P = 0.30). Moreover, IgGs purified from milk and plasma had equal neutralizing potencies against a tier 1 virus (r = 0.65; P < 0.0001), whereas only 1 out of 35 tested non-IgG milk fractions had detectable neutralization. These results suggest that plasma-derived IgG antibodies mediate the majority of the low-level HIV neutralization and ADCC activity in breast milk.
Asunto(s)
Formación de Anticuerpos , Anticuerpos Anti-VIH/análisis , Infecciones por VIH/inmunología , Inmunoglobulina G/análisis , Leche Humana/inmunología , Plasma/inmunología , Anticuerpos Neutralizantes/análisis , Citotoxicidad Celular Dependiente de Anticuerpos , Reacciones Cruzadas , Femenino , Humanos , Inmunoglobulina A/análisis , Pruebas de Neutralización , Productos del Gen env del Virus de la Inmunodeficiencia Humana/inmunologíaRESUMEN
INTRODUCTION: Correct and consistent condom use within an HIV-discordant partnership could prevent sexual transmission of human immunodeficiency virus (HIV). METHODS: Data on ever-married women from rural Malawi were obtained from the Malawi Diffusion and Ideational Change Project (MDICP) of 2006. We assessed the strength of association between religion and acceptability of condom use within marriage in general and also when one of the partners is suspected or known to be HIV infected. RESULTS: A total of 1,664 ever-married women participated in the MDICP 2006. Of these, 66.7% believed condom use was acceptable within marriage when one partner suspects or knows that the other was HIV infected; 38.2% believed condoms were acceptable within marriage generally. Only 13.8% reported ever having used condoms within the current or most recent marriage. Multivariate analysis found no difference in acceptability of condoms within marriage between Christians and Muslims, or between Catholics and all but one of the individual denominations assessed. CONCLUSION: Christian women in rural Malawi were no more or no less likely to accept condom use than Muslim women; there was also no difference in attitude toward condom use within marriage among Malawian women.
Asunto(s)
Condones/estadística & datos numéricos , Matrimonio/estadística & datos numéricos , Religión , Población Rural/estadística & datos numéricos , Adolescente , Adulto , Actitud , Catolicismo , Femenino , Infecciones por VIH/prevención & control , Humanos , Islamismo , Malaui , Protestantismo , Conducta Sexual , Factores Socioeconómicos , Adulto JovenRESUMEN
HIV transmission via breastfeeding accounts for a considerable proportion of infant HIV acquisition. However, the origin and evolution of the virus population in breast milk, the likely reservoir of transmitted virus variants, are not well characterized. In this study, HIV envelope (env) genes were sequenced from virus variants amplified by single-genome amplification from plasmas and milk of 12 chronically HIV-infected, lactating Malawian women. Maximum likelihood trees and statistical tests of compartmentalization revealed interspersion of plasma and milk HIV env sequences in the majority of subjects, indicating limited or no compartmentalization of milk virus variants. However, phylogenetic tree analysis further revealed monotypic virus variants that were significantly more frequent in milk (median proportion of identical viruses, 29.5%; range, 0 to 61%) than in plasma (median proportion of identical viruses, 0%; range, 0 to 26%) (P = 0.002), suggesting local virus replication in the breast milk compartment. Moreover, clonally amplified virus env genes in milk produced functional virus Envs that were all CCR5 tropic. Milk and plasma virus Envs had similar predicted phenotypes and neutralization sensitivities to broadly neutralizing antibodies in both transmitting and nontransmitting mothers. Finally, phylogenetic comparison of longitudinal milk and plasma virus env sequences revealed synchronous virus evolution and new clonal amplification of evolved virus env genes in milk. The limited compartmentalization and the clonal amplification of evolving, functional viruses in milk indicate continual seeding of the mammary gland by blood virus variants, followed by transient local replication of these variants in the breast milk compartment.
Asunto(s)
Evolución Molecular , Variación Genética , Infecciones por VIH/virología , VIH-1/clasificación , VIH-1/aislamiento & purificación , Leche Humana/virología , ARN Viral/genética , Análisis por Conglomerados , Femenino , VIH-1/genética , Humanos , Lactante , Recién Nacido , Malaui , Datos de Secuencia Molecular , Filogenia , Plasma/virología , Embarazo , Receptores CCR5/fisiología , Receptores del VIH/fisiología , Análisis de Secuencia de ADN , Homología de Secuencia , Tropismo Viral , Productos del Gen env del Virus de la Inmunodeficiencia Humana/genéticaRESUMEN
OBJECTIVE: To determine whether long lasting insecticide treated bed nets (LLINs) distributed free of charge to pregnant women at their first antenatal clinic visit in Kinshasa, DRC are used from the time of distribution to delivery and 6 months after delivery. METHODS: Women were enrolled into a cohort study at their first antenatal care (ANC) visit and provided LLINs free of charge. Reported use of these nets was then measured at the time of delivery (n = 328) and in a random sample of women (n = 100) 6 months post-delivery using an interviewer administered, structured questionnaire. RESULTS: At baseline, only 25% of women reported having slept under a bed net the night before the interview. At the time of delivery, after being provided an LLIN for free, this increased to 79%. Six months post-delivery (n = 100), 80% of women reported sleeping under a net with a child under the age of 5 the night before the interview. CONCLUSIONS: Freely distributed bed nets are acceptable, feasible and result in high usage. Free distribution of bed nets during antenatal clinic visits may be a highly effective way to rapidly increase the use of bed nets among both pregnant women and their newborn infants in areas with high levels of ANC attendance.
Asunto(s)
Ropa de Cama y Ropa Blanca/provisión & distribución , Insecticidas/administración & dosificación , Malaria/prevención & control , Complicaciones Parasitarias del Embarazo/prevención & control , Atención Prenatal/métodos , Adolescente , Adulto , Ropa de Cama y Ropa Blanca/economía , Ropa de Cama y Ropa Blanca/estadística & datos numéricos , Estudios de Cohortes , Conducta Cooperativa , República Democrática del Congo , Países en Desarrollo , Estudios de Factibilidad , Femenino , Conocimientos, Actitudes y Práctica en Salud , Promoción de la Salud/economía , Promoción de la Salud/métodos , Humanos , Cuidado del Lactante/métodos , Recién Nacido , Embarazo , Mujeres Embarazadas/psicología , Factores Socioeconómicos , Adulto JovenRESUMEN
BACKGROUND: To describe malaria knowledge, attitudes toward malaria and bed net use, levels of ownership and use of bed nets, and factors associated with ownership and use among pregnant women attending their first antenatal care (ANC) visit in Kinshasa, DRC. METHODS: Women attending their first ANC visit at one maternity in Kinshasa were recruited to take part in a study where they were given free insecticide treated bed nets (ITNs) and then followed up at delivery and 6 months post delivery to assess ITN use. This study describes the baseline levels of bed net ownership and use, attitudes towards net use and factors associated with net use RESULTS: Among 351 women interviewed at baseline, 115 (33%) already owned a bed net and 86 (25%) reported to have slept under the net the previous night. Cost was reported as the reason for not owning a net by 48% of the 236 women who did not own one. In multivariable analyses, women who had secondary school or higher education were 3.4 times more likely to own a net (95% CI 1.6-7.3) and 2.8 times more likely to have used a net (95% CI 1.3-6.0) compared to women with less education CONCLUSION: Distribution of ITNs in antenatal clinics in this setting is needed and feasible. The potential for ITN use by this target population is high.
Asunto(s)
Ropa de Cama y Ropa Blanca/provisión & distribución , Ropa de Cama y Ropa Blanca/estadística & datos numéricos , Conocimientos, Actitudes y Práctica en Salud , Insecticidas , Malaria/prevención & control , Propiedad , Complicaciones Parasitarias del Embarazo/prevención & control , Mujeres Embarazadas/psicología , Atención Prenatal/métodos , Adolescente , Adulto , Lechos , Niño , Protección a la Infancia , República Democrática del Congo/epidemiología , Escolaridad , Estudios de Factibilidad , Femenino , Humanos , Malaria/epidemiología , Estado Civil , Bienestar Materno , Análisis Multivariante , Paridad , Pobreza , Embarazo , Complicaciones Parasitarias del Embarazo/epidemiologíaAsunto(s)
Síndrome de Inmunodeficiencia Adquirida/complicaciones , Dihidropteroato Sintasa/genética , Mutación , Pneumocystis carinii/enzimología , Neumonía por Pneumocystis/tratamiento farmacológico , Adulto , Femenino , Humanos , Masculino , Persona de Mediana Edad , Pneumocystis carinii/genética , Neumonía por Pneumocystis/microbiología , EspañaRESUMEN
No disponible
Asunto(s)
Masculino , Femenino , Humanos , Síndrome de Inmunodeficiencia Adquirida/complicaciones , Dihidropteroato Sintasa/genética , Mutación , Pneumocystis carinii/enzimología , Neumonía por Pneumocystis/radioterapia , Pneumocystis carinii/genética , Neumonía por Pneumocystis/microbiología , EspañaRESUMEN
Placental histopathology was studied in a cohort of 204 women living in an area of low Plasmodium falciparum and P. vivax malaria transmission. Detection of malaria antenatally was active, by weekly peripheral blood smears, and all infections were treated. Significant histopathologic placental malaria changes (increased malaria pigment, cytotrophoblastic prominence, and presence of parasites) were found only in a minority of women who had P. falciparum infections in pregnancy. These changes were significantly more frequent in women with evidence of peripheral blood infection close to delivery and only in these cases were placental inflammatory cells increased. Antenatal P. vivax infection was associated only with the presence of malaria pigment in the placenta. All placental infections diagnosed by blood smear and 32.4% (12 of 37) diagnosed by histopathology were associated with patent peripheral parasitemia. This study indicates that prompt treatment of peripheral parasitemias during pregnancy limits placental pathology. The effect on birth weight reduction may not result from irreversible placental changes but from the acute insult of infection. These findings emphasize the importance of treating malaria in pregnancy promptly with effective antimalarial drugs.